Natasha Persaud

Investigators performed a literature review to better understand how delays in treatment might affect clinical outcomes in urologic cancer patients, including the risk of upstaging, recurrence, and mortality.

In a study of T2 to T3 RCC patients, lymph node dissection did not significantly improve overall survival.

Combination radiation treatment and radical prostatectectomy Gleason 9 to 10 prostate cancer are associated with similar cancer-specific mortality, a study found.

Bladder cuff resection improves survival, according to investigators.

Researchers estimated a low excess risk of prostate cancer death for favorable-risk patients undergoing active surveillance rather than surgery: 1.1% to 8.7% over 15 years.

Two-year prostate cancer survival rates only increased from 60% in 2004 to 63% in 2014.

In a study of men with bone metastases from metastatic castration-resistant prostate cancer, black men had no significantly greater risk of skeletal-related events than nonblack men.

Olaparib prolonged progression-free survival compared with abiraterone or enzalutamide in a phase 3 trial of men with metastatic castration-resistant prostate cancer who had certain DNA repair mutations and whose disease was progressing while receiving novel hormonal therapy.

In a study of SEER registry patients with renal cell carcinoma, variant histology subtypes were associated with higher cancer-specific mortality than grade 4 clear-cell carcinoma.

A study of patients aged 70 or younger with high-risk prostate cancer found that black and Hispanic race was associated with a greater likelihood of receiving nondefinitive treatment, with patients experiencing poor outcomes as a result.